Phase 2 N=32 Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=131 A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Phase 3 N=271 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Phase 2 N=18 Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Phase 2 N=4 Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Phase 2 N=42 Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Phase 2 N=65 A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
Phase 4 N=111 Treatment of Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Phase 2 N=129 Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Objective Response Rate — 25.8 percentage of participants
Phase 2 N=44 Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Phase 2 N=65 Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Phase 2 N=55 Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants
Phase 2 N=20 Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients
Peripheral T-cell Lymphoma
Primary: Complete Remission (CR) Rate — 3 Participants
Phase 2 N=13 Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Phase 2 N=53 Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
Phase 1 N=12 A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Phase 2 N=60 Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Overall Response Rate — 1; 1; 3; 1 Participants
Phase 2 N=49 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Phase 1 N=20 Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Phase 2 N=21 CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
Previously Untreated Peripheral T-cell Lymphoma
Primary: Complete Response Rate — 75 percentage of participants
Phase 2 N=33 A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants
Phase 2 N=34 S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rate — 31 percentage of participants
Phase 2 N=5 Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
Lymphoma
Primary: Overall Response Rate After 2 Courses of Treatment
Phase 3 N=71 A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
Phase 2 N=111 Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
Primary: Response Rate Per Independent Central Review — 32 of Patients who Responded
Phase 2 N=63 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-cell Chronic Lymphocytic Leukemia
Primary: Disease Relapse Rate — 18 Participants
Phase 2 N=9 Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma · Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Primary: Number of Patients With Grade 3 or Above Toxicities — 9 Participants
Phase 2 N=37 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Phase 2 N=12 Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
T Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate — 0.0 proportion of participants
Phase 2 N=23 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
T-cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepato-splenic T-cell Lymphoma
Primary: Overall Response Rate — 89.5 percentage of participants